BiomX (PHGE)
(Delayed Data from AMEX)
$0.98 USD
+0.04 (4.20%)
Updated Oct 16, 2024 03:56 PM ET
After-Market: $0.94 -0.04 (-4.03%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHGE 0.98 +0.04(4.20%)
Will PHGE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PHGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHGE
BiomX Stock Gains From Favorable Study Data Presentation on BX004
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
PHGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data
Other News for PHGE
BiomX announces mandatory unit separation
BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong Financial Turnaround and Promising ...
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
BiomX to present data from Phase 1b/2a study of BX004
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference